BACKGROUND: The effects of HIV infection and antiretroviral therapy (ART) on usual lipid levels have been reported. The effects of initiating versus deferring ART on high-density and low-density lipoprotein particle (HDL-P and LDL-P, respectively) concentrations and apolipoprotein (Apo) levels are not well described. METHODS: In a subgroup of participants not taking ART at study entry who were randomized in the Strategies for Management of Antiretroviral Therapy (SMART) trial to immediately initiate ART ('viral suppression group') or to defer it ('drug conservation group'), lipoprotein particle concentrations and ApoA1 and ApoB levels were measured at baseline and at 2 and 6 months following randomization. RESULTS: Compared with drug conservation group (n = 126), HDL-P and ApoA1 levels increased among viral suppression participants (n = 128) after starting ART. At 6 months, viral suppression participants had 13% higher total HDL-P (P < 0.001) and 9% higher ApoA1 (P < 0.001). LDL-P, very low density lipoprotein particle, and ApoB did not differ significantly between the viral suppression and drug conservation groups. Among viral suppression participants, predictors of HDL-P and ApoA1 increases included baseline levels of high-sensitivity C-reactive protein (hsCRP) and interleukin 6 (IL-6), but not HIV RNA level, CD4 cell count, or traditional cardiovascular disease risk factors. The effect of starting ART on changes in HDL-P and ApoA1 was greater for those with higher versus lower baseline levels of IL-6 (P = 0.001 and 0.08, respectively, for interaction) or hsCRP (P = 0.01 and 0.04, respectively, for interaction). CONCLUSION: HDL-P and ApoA1 increase following ART initiation, to a degree that depends on the degree of inflammation present at entry. These findings suggest that activation of inflammatory pathways contribute to HIV-associated changes in HDL.
RCT Entities:
BACKGROUND: The effects of HIV infection and antiretroviral therapy (ART) on usual lipid levels have been reported. The effects of initiating versus deferring ART on high-density and low-density lipoprotein particle (HDL-P and LDL-P, respectively) concentrations and apolipoprotein (Apo) levels are not well described. METHODS: In a subgroup of participants not taking ART at study entry who were randomized in the Strategies for Management of Antiretroviral Therapy (SMART) trial to immediately initiate ART ('viral suppression group') or to defer it ('drug conservation group'), lipoprotein particle concentrations and ApoA1 and ApoB levels were measured at baseline and at 2 and 6 months following randomization. RESULTS: Compared with drug conservation group (n = 126), HDL-P and ApoA1 levels increased among viral suppression participants (n = 128) after starting ART. At 6 months, viral suppression participants had 13% higher total HDL-P (P < 0.001) and 9% higher ApoA1 (P < 0.001). LDL-P, very low density lipoprotein particle, and ApoB did not differ significantly between the viral suppression and drug conservation groups. Among viral suppression participants, predictors of HDL-P and ApoA1 increases included baseline levels of high-sensitivity C-reactive protein (hsCRP) and interleukin 6 (IL-6), but not HIV RNA level, CD4 cell count, or traditional cardiovascular disease risk factors. The effect of starting ART on changes in HDL-P and ApoA1 was greater for those with higher versus lower baseline levels of IL-6 (P = 0.001 and 0.08, respectively, for interaction) or hsCRP (P = 0.01 and 0.04, respectively, for interaction). CONCLUSION: HDL-P and ApoA1 increase following ART initiation, to a degree that depends on the degree of inflammation present at entry. These findings suggest that activation of inflammatory pathways contribute to HIV-associated changes in HDL.
Authors: Bela F Asztalos; Ernst J Schaefer; Katalin V Horvath; Caitlin E Cox; Sally Skinner; Jul Gerrior; Sherwood L Gorbach; Christine Wanke Journal: Atherosclerosis Date: 2005-06-01 Impact factor: 5.162
Authors: Judith C Shlay; Glenn Bartsch; Grace Peng; Jack Wang; Carl Grunfeld; Cynthia L Gibert; Fehmida Visnegarwala; Sai Subhasree Raghavan; Ying Xiang; Martha Farrough; Harold E Perry; Donald Kotler; Wafaa M El-Sadr Journal: J Acquir Immune Defic Syndr Date: 2007-04-15 Impact factor: 3.731
Authors: James D Otvos; Dorothea Collins; David S Freedman; Irina Shalaurova; Ernst J Schaefer; Judith R McNamara; Hanna E Bloomfield; Sander J Robins Journal: Circulation Date: 2006-03-13 Impact factor: 29.690
Authors: Sean Emery; Jacqueline A Neuhaus; Andrew N Phillips; Abdel Babiker; Calvin J Cohen; Jose M Gatell; Pierre-Marie Girard; Birgit Grund; Matthew Law; Marcelo H Losso; Adrian Palfreeman; Robin Wood Journal: J Infect Dis Date: 2008-04-15 Impact factor: 5.226
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Zahedi Mujawar; Honor Rose; Matthew P Morrow; Tatiana Pushkarsky; Larisa Dubrovsky; Nigora Mukhamedova; Ying Fu; Anthony Dart; Jan M Orenstein; Yuri V Bobryshev; Michael Bukrinsky; Dmitri Sviridov Journal: PLoS Biol Date: 2006-10 Impact factor: 8.029
Authors: Daniel Fuster; Debbie M Cheng; Emily K Quinn; Kaku A Armah; Richard Saitz; Matthew S Freiberg; Jeffrey H Samet; Judith I Tsui Journal: AIDS Date: 2014-04-24 Impact factor: 4.177
Authors: Joyce L Sanchez; Peter W Hunt; Cavan S Reilly; Hiroyu Hatano; Gregory J Beilman; Alexander Khoruts; Jake S Jasurda; Ma Somsouk; Ann Thorkelson; Samuel Russ; Jodi Anderson; Steven G Deeks; Timothy W Schacker Journal: J Infect Dis Date: 2014-10-24 Impact factor: 5.226
Authors: Sarah E Stephenson; Carole L Wilson; Nell G Bond; Amitinder Kaur; Xavier Alvarez; Cecily C Midkiff; Lynn M Schnapp Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-09-09 Impact factor: 5.464
Authors: Salma S Syed; Rula S Balluz; Edmond K Kabagambe; William A Meyer; Susan Lukas; Craig M Wilson; Bill G Kapogiannis; Sharon A Nachman; John W Sleasman Journal: AIDS Res Hum Retroviruses Date: 2012-12-03 Impact factor: 2.205
Authors: Engi F Attia; Kathleen M Akgün; Cherry Wongtrakool; Matthew Bidwell Goetz; Maria C Rodriguez-Barradas; David Rimland; Sheldon T Brown; Guy W Soo Hoo; Joon Kim; Patty J Lee; Lynn M Schnapp; Amir Sharafkhaneh; Amy C Justice; Kristina Crothers Journal: Chest Date: 2014-12 Impact factor: 9.410